Compared side by side
BPC-157 vs VIP: how they differ
The short answer
BPC-157 is a peptide derived from a protective protein in human gastric juice that, in animal studies, speeds the repair of tendons, ligaments, muscle and gut lining. VIP is a neuropeptide the body uses to relax blood vessels and steer immune signaling, used mostly as a nasal spray in protocols for chronic inflammatory response syndrome (CIRS) and mold illness. VIP’s human evidence is small open-label case series, and BPC-157’s is three small uncontrolled pilots.
Side by side
| Compared | BPC-157 | VIP |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Body Protection Compound 157, BPC157 | Vasoactive Intestinal Peptide, VIP neuropeptide |
| What it is | A peptide derived from a protective protein in your stomach. | A neuropeptide your body uses to relax blood vessels and steer immune signaling; in animal studies it's a powerful anti-inflammatory. |
| How it works | Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining. | Neuropeptide with potent anti-inflammatory effects in animal and cell studies; it also relaxes blood vessels and helps regulate the autonomic nervous system. Its effect on mast cells is mixed: in human mast cells in the lab it can trigger them. Used mainly in CIRS (chronic inflammatory response syndrome) and mold-illness protocols, a use that rests on open-label case series from one clinical group. |
| Commonly reported | Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots. | Flushing or lightheadedness soon after a dose, especially early on, and for people on those protocols a slow lift in brain fog and fatigue over weeks to months. The human evidence is small open-label case series. |
| Studied range | Research range: 200–500 mcg. Studied in research — not a recommendation. | Research range: 50 mcg. Studied in research — not a recommendation. |
| How often | Once or twice daily | 2x daily, intranasal |
| Half-life | ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes) | ~2 min IV; intranasal lasts longer locally |
| Route | SubQ injection, IM injection, Oral (less studied) | Intranasal (primary), SubQ injection |
| Typical run | Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely. | Used in defined cycles in CIRS protocols, often 4+ weeks. Practitioner guidance recommended. |
| Evidence | Emerging: primarily preclinical / limited human data | Moderate: animal studies + some human data |
| Common side effects | Nausea (rare), injection site irritation, vivid dreams, dizziness | Flushing, hypotension at higher doses, headache, lightheadedness |
- Category
- BPC-157Healing & recovery
- VIPHealing & recovery
- Also known as
- BPC-157Body Protection Compound 157, BPC157
- VIPVasoactive Intestinal Peptide, VIP neuropeptide
- What it is
- BPC-157A peptide derived from a protective protein in your stomach.
- VIPA neuropeptide your body uses to relax blood vessels and steer immune signaling; in animal studies it's a powerful anti-inflammatory.
- How it works
- BPC-157Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
- VIPNeuropeptide with potent anti-inflammatory effects in animal and cell studies; it also relaxes blood vessels and helps regulate the autonomic nervous system. Its effect on mast cells is mixed: in human mast cells in the lab it can trigger them. Used mainly in CIRS (chronic inflammatory response syndrome) and mold-illness protocols, a use that rests on open-label case series from one clinical group.
- Commonly reported
- BPC-157Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
- VIPFlushing or lightheadedness soon after a dose, especially early on, and for people on those protocols a slow lift in brain fog and fatigue over weeks to months. The human evidence is small open-label case series.
- Studied range
- BPC-157Research range: 200–500 mcg. Studied in research — not a recommendation.
- VIPResearch range: 50 mcg. Studied in research — not a recommendation.
- How often
- BPC-157Once or twice daily
- VIP2x daily, intranasal
- Half-life
- BPC-157~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
- VIP~2 min IV; intranasal lasts longer locally
- Route
- BPC-157SubQ injection, IM injection, Oral (less studied)
- VIPIntranasal (primary), SubQ injection
- Typical run
- BPC-157Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.
- VIPUsed in defined cycles in CIRS protocols, often 4+ weeks. Practitioner guidance recommended.
- Evidence
- BPC-157Emerging: primarily preclinical / limited human data
- VIPModerate: animal studies + some human data
- Common side effects
- BPC-157Nausea (rare), injection site irritation, vivid dreams, dizziness
- VIPFlushing, hypotension at higher doses, headache, lightheadedness
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
BPC-157
- Day 1–7 Week one: early hints, for some
- Day 7–14 Pain often starts to ease
- Day 14–21 Pain often eases by week three
- Day 21–28 Many report a calmer gut
- Day 28–42 The slower part of repair
- Day 42–56 Six weeks in: taking stock
- Day 84+ Past week 12, the data runs thin
VIP
- Day 1–14 The first two weeks
- Day 14–60 A slow arc, not a quick change
- Day 60–120 The long arc
Together or one or the other
BPC-157 and VIP are a common stack: VIP lists BPC-157 among its common stacks.
Community · VIP
An inflammation-focused trio
Three angles at once: VIP to damp inflammation, LL-37 against microbes, and BPC-157 for gut and tissue repair. Used together in some mold-illness practitioner protocols; no study has tested the combination.
Questions people ask
How long do BPC-157 and VIP last?
The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes). The half-life of VIP is ~2 min IV; intranasal lasts longer locally.
How often are BPC-157 and VIP taken?
BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied). VIP: 2x daily, intranasal. Routes: Intranasal (primary), subQ injection.
How are BPC-157 and VIP dosed in research?
The research range for BPC-157 is 200–500 mcg. The research range for VIP is 50 mcg. Studied in research — not a recommendation.
What are the common side effects of BPC-157 and VIP?
For BPC-157, the library lists: nausea (rare), injection site irritation, vivid dreams, dizziness. For VIP: flushing, hypotension at higher doses, headache, lightheadedness.
Are BPC-157 and VIP taken together?
BPC-157 and VIP are a common stack: VIP lists BPC-157 among its common stacks. Three angles at once: VIP to damp inflammation, LL-37 against microbes, and BPC-157 for gut and tissue repair. Used together in some mold-illness practitioner protocols; no study has tested the combination.